share_log

Intuitive Surgical | 8-K: INTUITIVE ANNOUNCES SECOND QUARTER EARNINGS

Intuitive Surgical | 8-K: INTUITIVE ANNOUNCES SECOND QUARTER EARNINGS

直覺外科公司 | 8-K:直覺公佈第二季度業績
美股SEC公告 ·  2024/07/18 01:09

Moomoo AI 已提取核心訊息

Intuitive Surgical announced strong Q2 2024 results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew 17% year-over-year, while the installed base expanded 14% to 9,203 systems. The company placed 341 da Vinci systems, including 70 new da Vinci 5 models.GAAP net income rose to $527 million, or $1.46 per diluted share, up from $421 million, or $1.18 per share, in Q2 2023. Non-GAAP net income reached $641 million, or $1.78 per diluted share, compared to $507 million, or $1.42 per share, last year. Instruments and accessories revenue grew 16% to $1.24 billion, driven by procedure volume growth.The company ended the quarter with $7.68 billion in cash and investments, an increase of $360 million. Intuitive Surgical noted that the first half of 2024 saw no significant COVID-19 disruptions to procedure volumes, unlike the previous year which experienced some impact in China during Q1 2023.
Intuitive Surgical announced strong Q2 2024 results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew 17% year-over-year, while the installed base expanded 14% to 9,203 systems. The company placed 341 da Vinci systems, including 70 new da Vinci 5 models.GAAP net income rose to $527 million, or $1.46 per diluted share, up from $421 million, or $1.18 per share, in Q2 2023. Non-GAAP net income reached $641 million, or $1.78 per diluted share, compared to $507 million, or $1.42 per share, last year. Instruments and accessories revenue grew 16% to $1.24 billion, driven by procedure volume growth.The company ended the quarter with $7.68 billion in cash and investments, an increase of $360 million. Intuitive Surgical noted that the first half of 2024 saw no significant COVID-19 disruptions to procedure volumes, unlike the previous year which experienced some impact in China during Q1 2023.
直覺外科公司公佈了2024年第二季度的強勁業績,營業收入增長14%至20.1億美金。全球達芬奇手術數量同比增長17%,而安裝基礎擴大14%至9,203台。公司共安裝了341臺達芬奇系統,包括70臺新的達芬奇5型號。根據GAAP標準,凈利潤升至52700萬美元,或每股稀釋後1.46美元,較2023年第二季度的42100萬美元,或每股1.18美元有所增加。根據非GAAP標準,凈利潤達到64100萬美元,或每股稀釋後1.78美元,而去年的數字爲50700萬美元,或每股1.42美元。儀器和配件的營業收入增長16%至12.4億美金,主要受手術成交量增長的推動。公司結束本季度時現金和投資總額爲76.8億美金,增加了36000萬美元。直覺外科公司指出,2024年上半年沒有出現對手術成交量的重大COVID-19干擾,與去年第一季度在中國經歷的一些影響不同。
直覺外科公司公佈了2024年第二季度的強勁業績,營業收入增長14%至20.1億美金。全球達芬奇手術數量同比增長17%,而安裝基礎擴大14%至9,203台。公司共安裝了341臺達芬奇系統,包括70臺新的達芬奇5型號。根據GAAP標準,凈利潤升至52700萬美元,或每股稀釋後1.46美元,較2023年第二季度的42100萬美元,或每股1.18美元有所增加。根據非GAAP標準,凈利潤達到64100萬美元,或每股稀釋後1.78美元,而去年的數字爲50700萬美元,或每股1.42美元。儀器和配件的營業收入增長16%至12.4億美金,主要受手術成交量增長的推動。公司結束本季度時現金和投資總額爲76.8億美金,增加了36000萬美元。直覺外科公司指出,2024年上半年沒有出現對手術成交量的重大COVID-19干擾,與去年第一季度在中國經歷的一些影響不同。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息